[go: up one dir, main page]

GR1007327B - Soluble triggering receptor s-trem-1 used for activating the myeloid cells and controlling the efficiency of the peptic ulcer treatment - Google Patents

Soluble triggering receptor s-trem-1 used for activating the myeloid cells and controlling the efficiency of the peptic ulcer treatment

Info

Publication number
GR1007327B
GR1007327B GR20070100514A GR20070100514A GR1007327B GR 1007327 B GR1007327 B GR 1007327B GR 20070100514 A GR20070100514 A GR 20070100514A GR 20070100514 A GR20070100514 A GR 20070100514A GR 1007327 B GR1007327 B GR 1007327B
Authority
GR
Greece
Prior art keywords
peptic ulcer
efficiency
controlling
myeloid cells
trem
Prior art date
Application number
GR20070100514A
Other languages
Greek (el)
Other versions
GR20070100514A (en
Inventor
Ευαγγελος Γιαμαρελλος-Μπουρμπουλης
Βασιλειος Κουσουλας
Original Assignee
Ευαγγελος Γιαμαρελλος-Μπουρμπουλης
Βασιλειος Κουσουλας
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ευαγγελος Γιαμαρελλος-Μπουρμπουλης, Βασιλειος Κουσουλας filed Critical Ευαγγελος Γιαμαρελλος-Μπουρμπουλης
Priority to GR20070100514A priority Critical patent/GR1007327B/en
Publication of GR20070100514A publication Critical patent/GR20070100514A/en
Publication of GR1007327B publication Critical patent/GR1007327B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to the use of a polypeptide (sTREM-1)-a soluble receptor triggering the myeloid cells- determined in the blood serum of patients suffering from peptic ulcer. The patients are subjected to blood examinations before and after the treatment administrated for healing the peptic ulcer. The method in question aims at controlling the efficiency of the ulcer therapy and evaluating the potential necessity of a further therapeutic intervention.
GR20070100514A 2007-08-08 2007-08-08 Soluble triggering receptor s-trem-1 used for activating the myeloid cells and controlling the efficiency of the peptic ulcer treatment GR1007327B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20070100514A GR1007327B (en) 2007-08-08 2007-08-08 Soluble triggering receptor s-trem-1 used for activating the myeloid cells and controlling the efficiency of the peptic ulcer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20070100514A GR1007327B (en) 2007-08-08 2007-08-08 Soluble triggering receptor s-trem-1 used for activating the myeloid cells and controlling the efficiency of the peptic ulcer treatment

Publications (2)

Publication Number Publication Date
GR20070100514A GR20070100514A (en) 2009-03-17
GR1007327B true GR1007327B (en) 2011-06-27

Family

ID=40481618

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20070100514A GR1007327B (en) 2007-08-08 2007-08-08 Soluble triggering receptor s-trem-1 used for activating the myeloid cells and controlling the efficiency of the peptic ulcer treatment

Country Status (1)

Country Link
GR (1) GR1007327B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11186636B2 (en) 2017-04-21 2021-11-30 Amgen Inc. Anti-human TREM2 antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081233A1 (en) * 2003-03-10 2004-09-23 Bioxell S.P.A. Diagnostic and prognostic compounds and method
WO2005071408A1 (en) * 2004-01-27 2005-08-04 Bioxell S.P.A. Method of diagnosing infectious disease by measuring the level of soluble trem-1 in a sample
WO2006056492A1 (en) * 2004-11-29 2006-06-01 Bioxell Spa Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081233A1 (en) * 2003-03-10 2004-09-23 Bioxell S.P.A. Diagnostic and prognostic compounds and method
WO2005071408A1 (en) * 2004-01-27 2005-08-04 Bioxell S.P.A. Method of diagnosing infectious disease by measuring the level of soluble trem-1 in a sample
WO2006056492A1 (en) * 2004-11-29 2006-06-01 Bioxell Spa Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Base de données EMBL. Entrée HS417D01B Numéro d'accès D61556; 31 août 1995 FUJIWARA T. ET AL, EMBL NUCLEOTIDE SEQUENCE, XP002008028 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11186636B2 (en) 2017-04-21 2021-11-30 Amgen Inc. Anti-human TREM2 antibodies and uses thereof

Also Published As

Publication number Publication date
GR20070100514A (en) 2009-03-17

Similar Documents

Publication Publication Date Title
MX2009011540A (en) Treatment of movement disorders by a combined use of botulinum toxin and muscle stimulation.
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
PL1885382T3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
JP2013523349A5 (en)
MY161844A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12018500639A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
MX2013002488A (en) Methods and compositions for delivering interleukin-1 receptor antagonist.
IN2012DN06309A (en)
WO2021035222A3 (en) Apparatus for systemic human enhancement from administration of frequency therapy including enhanced stem cell and genetic therapy
BR112013005673A2 (en) use of lysosomal acid lipase for treatment of lysosomal acid lipase deficiency in patients
GB2477256A (en) Medicament and method of diagnosis
PL1778833T3 (en) Methods of using regenerative cells to promote wound healing
EA201290278A1 (en) METHOD OF TREATING HEART FAILURE WITH THE USE OF STRESS-SCRATCH-LIKE PEPTIDES
WO2011133957A3 (en) Devices for delivering neuro-electro-adaptive therapy (neat)
HRP20161147T1 (en) PHARMACEUTICAL COMPOSITION AND PROCEDURE OF ITS MANUFACTURING
Pasek et al. Comparison of the efficacy of topical hyperbaric oxygen therapy alone vs a combination of physical methods including topical hyperbaric oxygen therapy, magnetotherapy, and low‐energy light therapy in the treatment of venous leg ulcers
GR1007327B (en) Soluble triggering receptor s-trem-1 used for activating the myeloid cells and controlling the efficiency of the peptic ulcer treatment
CN203898412U (en) Fixing device for department of orthopaedics
DK1778834T5 (en) Methods for the use of regenerative cells in the treatment of renal diseases and disorders
WO2010103475A3 (en) Use of serine protease inhibitors in the treatment of neutropenia
Loder et al. QS59. Pulsed-release Dexamethasone-loaded Microspheres Mitigate Scar Contracture and Adhesions in Composite Tissue Burn Reconstruction
WO2008100567A3 (en) Thrombin peptide derivatives for treating fractures in osteopenic patients
UA70188C2 (en) Method for treating patients with chronic cardiac insufficiency
Saggini et al. Pharmaceutical Sciences Research

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20110714

ML Lapse due to non-payment of fees

Effective date: 20140305